Key result
In female mice, 2-methoxyestradiol protects against AngII-induced hypertension and associated pathogenesis by inhibiting LOX/12(S)-HETE actions in the paraventricular nucleus.
Why the study?
Previous findings indicated 12(S)-HETE promotes AngII-induced hypertension while 2-methoxyestradiol protects against it in the PVN, prompting researchers to test whether 2-methoxyestradiol acts by inhibiting LOX/12(S)-HETE in the PVN.
Does 2-methoxyestradiol prevent AngII-induced hypertension and associated pathogenesis in female mice?
Does 2-methoxyestradiol prevent AngII-induced hypertension and associated pathogenesis in female mice?
2-methoxyestradiol protects against AngII-induced hypertension in female mice by inhibiting LOX/12(S)-HETE actions in the paraventricular nucleus, highlighting a potential therapeutic pathway for postmenopausal hypertension.
BACKGROUND: Our previous findings that arachidonic acid-12/15-lipoxygenase (LOX)-generated metabolite 12(S)-HETE contributes to angiotensin II (AngII)-induced hypertension and 17β-estradiol protects from AngII-induced hypertension via its cytochrome P450 (CYP)1B1-generated metabolite 2-methoxyestradiol in the paraventricular nucleus (PVN) in female mice led us to test the hypothesis that 2-methoxyestradiol acts by inhibiting the LOX/12(S)-HETE in the PVN. METHODS: AngII was infused subcutaneously by osmotic pumps for 2 weeks in wild-type, LOX-knockout (LOXKO), and CYP1B1KO female mice. The blood pressure was measured by tail-cuff/radiotelemetry. Adenovirus (Ad)-GFP (green fluorescence protein)-LOX-short hairpin RNA, Ad-GFP-LOX-DNA, 12(S)-HETE, and 2-methoxyestradiol were injected selectively in PVN or intracerebroventricularly. Histological, immunohistochemical, and biochemical techniques were used to determine pathophysiological changes caused by various interventions. RESULTS: AngII-induced hypertension that was exaggerated in CYP1B1KO compared with wild-type mice was minimized by PVN-LOX knockdown with Ad-LOX-short hairpin RNA and restored by PVN-LOX reconstitution with Ad-LOX-DNA in intact-LOXKO mice and exacerbated in ovariectomized-LOXKO mice. Furthermore, intracerebroventricular-12(S)-HETE restored AngII-induced increases in blood pressure, autonomic impairment, neuroinflammation, and renal pathogenesis in intact-LOXKO mice, which were exacerbated in ovariectomized-LOXKO mice. Intracerebroventricular-2-methoxyestradiol that reduced the LOX expression and 12(S)-HETE content in PVN minimized AngII effects mentioned above in ovariectomized-LOXKO mice transduced with intracerebroventricular-Ad-LOX-DNA. CONCLUSIONS: These data suggest that 2-methoxyestradiol protects against AngII-induced hypertension and associated pathogenesis, most likely by inhibiting LOX/12(S)-HETE actions in the PVN of female mice. Therefore, the selective LOX inhibitors or 12(S)-HETE receptor antagonists could be useful in treating hypertension and its pathogenesis in postmenopausal, hypoestrogenic women or females with ovarian failure.
No takes yet. Share an insight, caveat, or question.
Dutta et al. (2025) studied AngII-induced hypertension. 2-methoxyestradiol and LOX/12(S)-HETE modulation vs. Wild-type or control conditions was evaluated on Blood pressure, autonomic impairment, neuroinflammation, and renal pathogenesis. In female mice, 2-methoxyestradiol protects against AngII-induced hypertension and associated pathogenesis by inhibiting LOX/12(S)-HETE actions in the paraventricular nucleus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: